Centelion

Aventis Pharma S.a.

Institut National De La Sante Et De La Recherche Medicale

Innavirvax

Anosys, Inc., Institute Curie

Minka Therapeutics

Joël Crouzet

Daniel Scherman

Pierre Wils

Béatrice Cameron

Françis Blanche

Sebastian Amigorena

Patrice Debre

Bruno Pitard

Fabienne Soubrier

Vincent Vieillard

Olivier Dhellin

Raphaël Ho Tsong Fang

Dominique Desfontaines

Philippe Rameau

The present invention relates to the field of vaccines directed against viruses of the HIV family. More particularly, it relates to an immunogenic compound comprising a peptide of the following formula (I) NH2-[Nt]y-P-W-N-X-S-X2-S-N-X3-X4-X-X6-X7-I-W-[Ct]z-COOH (I) which is covalently linked to a carrier protein consisting of a CRM197 protein. It also concerns a composition containing this immunogenic compound and the uses of these immunogenic compounds and compositions for preventing and/or treating a condition caused by the infection of an individual with a HIV virus.

Immunogenic compounds comprising HIV GP41 peptide coupled to CRM197 carrier protein

A method for double-stranded DNA purification, by which a solution containing DNA in a mixture with other components is passed over a support on which is covalently coupled an oligonucleotide capable of hybridizing with a specific sequence present on the DNA to form a triple helix.

Purification of a triple helix formation with an immobilized obligonucleotide

Purification of a triple helix formation with an immobilized oligonucleotide

The invention concerns a composition containing stabilised particles of cationic transfection agent(s)/nucleic acid complexes characterised in that it includes besides said transfection agent and nucleic acid at least a non-ionic surfactant in sufficient amount for preventing the aggregation of the particles in course of time. In a preferred embodiment, the surfactant is a polyoxyalkylene or a derivative thereof.

Formulation of stabilized cationic transfection agent(s)/nucleic acid particles

Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.

Purification of a triple heli formation with an immobilized oligonucleotide

A circular DNA molecule, useful for gene therapy, comprising at least one nucleic acid sequence of interest, characterized in that the region allowing the replication thereof has an origin of replication with a functionality in a host cell that requires the presence of at least one specific protein foreign to said host cell. A method for preparing same, cells incorporating said DNA molecules and uses thereof in gene therapy are also described.

Circular DNA molecule with conditional origin of replication, method for preparing the same and use thereof in gene therapy

This invention relates to a method of preparing membrane vesicles from a biological sample, characterised in that it comprises at least one anion exchange and/or gel permeation chromatography treatment of the sample. The invention is used to prepare vesicles of varied origins and types, particularly from antigen presenting cells or tumoral cells. The invention also relates to the vesicles obtained in this way and their uses.

Method for preparing membrane vesicles

The invention concerns a composition containing stabilized particles of cationic transfection agents/nucleic acid complexes characterized in that it includes besides said transfection agent and nucleic acid at least a non-ionic surfactant in sufficient amount for preventing the aggregation of the particles in course of time. In a preferred embodiment, the surfactant is a polyoxyalkylene or a derivative thereof.

Formulation of stabilized cationic transfection agent(s) /nucleic acid particles

Growing community of inventors

Sceaux, France

Joël Crouzet